Search Results - "Haas, Gabriel P."

Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters by Poondru, Srinivasu, Ghicavii, Vitalii, Khosravan, Reza, Manchandani, Pooja, Heo, Nakyo, Moy, Selina, Wojtkowski, Tomasz, Patton, Melanie, Haas, Gabriel P.

“…Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to…”
Get full text

Neoadjuvant Enzalutamide Prior to Prostatectomy by Montgomery, Bruce, Tretiakova, Maria S, Joshua, Anthony M, Gleave, Martin E, Fleshner, Neil, Bubley, Glenn J, Mostaghel, Elahe A, Chi, Kim N, Lin, Daniel W, Sanda, Martin, Novotny, William, Wu, Kenneth, Kantoff, Philip W, Marck, Brett T, Plymate, Stephen, Balk, Steven P, Nelson, Peter S, Matsumoto, Alvin M, Lis, Rosina T, Kibel, Adam, Haas, Gabriel P, Krivoshik, Andrew, Hannah, Alison, Taplin, Mary-Ellen

“…Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate…”
Get full text

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design by Freedland, Stephen J, De Giorgi, Ugo, Gleave, Martin, Rosbrook, Brad, Shen, Qi, Sugg, Jennifer, Haas, Gabriel P, Shore, Neal D

“…IntroductionLimited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate…”
Get full text

Expression of Prostate‐Specific Membrane Antigen in Normal and Malignant Human Tissues by Kinoshita, Yoshihisa, Kuratsukuri, Katsuyuki, Landas, Steve, Imaida, Katsumi, Rovito, Peter M., Wang, Ching Y., Haas, Gabriel P.

“…Background Prostate‐specific membrane antigen (PSMA) is upregulated in androgen‐dependent prostate carcinoma and it has been targeted for immunotherapy and…”
Get full text

A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy by Bianco, Fernando J, Albala, David M, Belkoff, Laurence H, Miles, Brian J, Peabody, James O, He, Weizhong, Bradt, Jason S, Haas, Gabriel P, Ahlering, Thomas E

“…Purpose Bladder dysfunction influences recovery of urinary continence after radical prostatectomy. We performed a multicenter, randomized, double-blind study…”
Get full text

Association of MnSOD AA Genotype with the Progression of Prostate Cancer by Iguchi, Taro, Wang, Ching Y, Delongchamps, Nicolas B, Kato, Minoru, Tamada, Satoshi, Yamasaki, Takeshi, de la Roza, Gustavo, Nakatani, Tatsuya, Haas, Gabriel P

“…To investigate whether manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with the clinical significance of prostate cancer. Prostates…”
Get full text

An update on enzalutamide in the treatment of prostate cancer by Merseburger, Axel S., Haas, Gabriel P., von Klot, Christoph-A.

“…Enzalutamide is an oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. In the randomized phase III AFFIRM…”
Get full text

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy by Haas, Gabriel P., M.D, Scher, Howard I., M.D

Get full text

Saturation biopsies for prostate cancer: current uses and future prospects by Delongchamps, Nicolas B, Haas, Gabriel P

“…There is a trend towards increasing the number of cores sampled during ultrasound-guided prostate biopsy in an attempt to increase the likelihood of detecting…”
Get full text

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer by Armstrong, Andrew J, Azad, Arun A, Iguchi, Taro, Szmulewitz, Russell Z, Petrylak, Daniel P, Holzbeierlein, Jeffrey, Villers, Arnauld, Alcaraz, Antonio, Alekseev, Boris, Shore, Neal D, Gomez-Veiga, Francisco, Rosbrook, Brad, Zohren, Fabian, Yamada, Shunsuke, Haas, Gabriel P, Stenzl, Arnulf

“…JCO In primary analysis, enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with…”
Get full text

A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval by Haas, Gabriel P., M.D., F.A.C.S, Scher, Howard I., M.D

Get full text

The spectrum of eosinophilic cystitis in males: case series and literature review by Popescu, Oana-Eugenia, Landas, Steve K, Haas, Gabriel P

“…Eosinophilic cystitis (EC) is an inflammatory condition of the bladder that has been linked to food allergens, infectious agents, drugs, and other…”
Get full text

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer by Freedland, Stephen J., de Almeida Luz, Murilo, De Giorgi, Ugo, Gleave, Martin, Gotto, Geoffrey T., Pieczonka, Christopher M., Haas, Gabriel P., Kim, Choung-Soo, Ramirez-Backhaus, Miguel, Rannikko, Antti, Tarazi, Jamal, Sridharan, Swetha, Sugg, Jennifer, Tang, Yiyun, Tutrone, Ronald F., Venugopal, Balaji, Villers, Arnauld, Woo, Henry H., Zohren, Fabian, Shore, Neal D.

“…In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared…”
Get full text

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses by Armstrong, Andrew J, Shore, Neal D, Szmulewitz, Russell Z, Petrylak, Daniel P, Holzbeierlein, Jeffrey, Villers, Arnauld, Azad, Arun, Alcaraz, Antonio, Alekseev, Boris, Iguchi, Taro, Gomez-Veiga, Francisco, Rosbrook, Brad, Lee, Ho-Jin, Haas, Gabriel P, Stenzl, Arnulf

“…Enzalutamide plus androgen deprivation therapy has previously been shown to improve clinical outcomes in men with metastatic hormone-sensitive prostate cancer…”
Get full text

MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status by Iguchi, Taro, Sugita, Shozo, Wang, Ching Y, Newman, Nancy B, Nakatani, Tatsuya, Haas, Gabriel P

“…Background: Cigarette smoke contains carcinogenic aromatic and heterocyclic amines that are metabolized by N-acetyltransferase (NAT). These carcinogens also…”
Get full text

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES by Armstrong, Andrew J., Iguchi, Taro, Azad, Arun A., Villers, Arnauld, Alekseev, Boris, Petrylak, Daniel P., Szmulewitz, Russell Z., Alcaraz, Antonio, Shore, Neal D., Holzbeierlein, Jeffrey, Gomez-Veiga, Francisco, Rosbrook, Brad, Zohren, Fabian, Haas, Gabriel P., Gourgiotti, Georgia, El-Chaar, Nader, Stenzl, Arnulf

“…In this post hoc analysis of the ARCHES trial, enzalutamide plus androgen deprivation therapy improved radiographic progression-free survival and overall…”
Get full text

The worldwide epidemiology of prostate cancer: perspectives from autopsy studies by Haas, Gabriel P, Delongchamps, Nicolas, Brawley, Otis W, Wang, Ching Y, de la Roza, Gustavo

“…Prostate cancer is the most frequently diagnosed non-skin cancer in the United States and the third leading cause of cancer deaths. International trends in the…”
Get more information

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial by Saad, Fred, de Bono, Johann, Shore, Neal, Fizazi, Karim, Loriot, Yohann, Hirmand, Mohammad, Franks, Billy, Haas, Gabriel P, Scher, Howard I

“…Abstract Background Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the…”
Get full text

Temporal trends and racial disparities in global prostate cancer prevalence by Rebbeck, Timothy R, Haas, Gabriel P

“…Data from 58 autopsy studies of latent prostate cancer from 1898-2013 were identified and analyzed accounting for histopathological methods, which may have…”
Get more information

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups by Stenzl, Arnulf, Szmulewitz, Russell Z., Petrylak, Daniel, Holzbeierlein, Jeffrey, Villers, Arnauld, Azad, Arun, Alcaraz, Antonio, Alekseev, Boris, Iguchi, Taro, Shore, Neal D., Gomez‐Veiga, Francisco, Ivanescu, Cristina, Rosbrook, Brad, Ramaswamy, Krishnan, Ganguli, Arijit, Haas, Gabriel P., Armstrong, Andrew J.

“…Background Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression‐free survival versus ADT alone in patients with metastatic…”
Get full text